Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

RHEUMATOID ARTHRITIS

2021 ACR guideline reflects changes in RA treatment

Nature Reviews Rheumatology volume 17, pages 513–514 (2021)Cite this article

Subjects

The 2021 ACR guideline for the treatment of rheumatoid arthritis provides an update on several important topics, including the use of targeted synthetic DMARDs (tsDMARDs). But how does the new guideline compare to EULAR recommendations, and is the growing importance of tsDMARDs adequately accounted for?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Singh, J. A. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 68, 1–25 (2015).

    Article  Google Scholar 

  2. Fraenkel, L. et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. https://doi.org/10.1002/art.41752 (2021).

    Article  PubMed  Google Scholar 

  3. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79, 685–699 (2020).

    Article  CAS  Google Scholar 

  4. Toupin-April, K. et al. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. Semin. Arthritis Rheum. 51, 593–600 (2021).

    Article  Google Scholar 

  5. Albrecht, K. & Zink, A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res. Ther. 23, 68 (2017).

    Article  Google Scholar 

  6. Alten, R. & Mischkewitz, M. New concepts to reduce glucocorticoid toxicity. Joint Bone Spine. 86, 715–723 (2019).

    Article  CAS  Google Scholar 

  7. Curtis, J. R. et al. Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remissions. Arthritis Rheumatol. 73, 759–768 (2021).

    Article  CAS  Google Scholar 

  8. Liu, B. S. et al. A decade of jakinibs: what we have learned and what may be the future. Arthritis Rheumatol. https://doi.org/10.1002/art.41906 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Van Vollenhoven, R. et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active-comparator-controlled trial. Arthritis Rheumatol. 72, 1607–1620 (2020).

    Article  Google Scholar 

  10. Pfizer. Pfizer shares co-primary endpoint results from post-marketing required safety study of Xeljanz® (tofacitinib) in subjects with rheumatoid arthritis (RA). Businesswire.com https://www.businesswire.com/news/home/20210127005184/en/ (2021).

Download references

Author information

Authors and Affiliations

  1. Internal Medicine, Rheumatology, Clinical Immunology and Osteology, Schlosspark-Klinik, Charité University Medicine Berlin, Berlin, Germany

    Rieke Alten & Max Mischkewitz

Authors
  1. Rieke Alten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Max Mischkewitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rieke Alten.

Ethics declarations

Competing interests

R.A. declares that she has received honoraria and research grants from Abbvie, BMS, Galalapagos, Gilead, Janssen, Lilly, MSD, Novartis and Pfizer. M.M. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alten, R., Mischkewitz, M. 2021 ACR guideline reflects changes in RA treatment. Nat Rev Rheumatol 17, 513–514 (2021). https://doi.org/10.1038/s41584-021-00667-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-021-00667-2

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing